Amplyx Pharmaceuticals Announces Presentations at IDWeek 2017

Presentation of multiple preclinical and clinical data from APX001 antifungal program

SAN DIEGO September 21, 2017 – Amplyx Pharmaceuticals, a biotechnology company developing novel antimicrobial agents for life-threatening fungal infections, today announced that seven posters from the APX001 development program will be presented at the Infectious Diseases Society of America (IDSA) IDWeek 2017, being held in San Diego, CA, from October 4 to 8, 2017.

For the first time, the Company and its collaborators will present data from both APX001 preclinical and Phase 1 clinical programs. APX001 is a broad-spectrum antifungal drug with a novel mechanism of action for the treatment of life-threatening, invasive fungal infections caused by Candida, Aspergillus and by rare, hard-to-treat molds, including strains that are resistant to standard of care antifungal therapy. Intravenous and oral formulations of APX001 have been evaluated in two Phase 1 clinical trials. Phase 2 studies are planned for initiation later this year.   

The schedule for presentations by Amplyx Pharmaceuticals and its collaborators is as follows:

1510. Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
Poster Abstract Session: Preclinical Study with New Antibiotics and Antifungals
Presenter: Emily Larkin, Case Western Reserve University
Date/Time: Friday, October 6, 2017/12:30 PM-2:00 PM
Room: Poster Hall CD

1513. Absorption, Distribution, and Excretion of 14C‑APX001 after Single-Dose Administration to Rats and Monkeys
Poster Abstract Session: Preclinical Study with New Antibiotics and Antifungals
Presenter: Ciara Kennedy, Ph.D., Amplyx Pharmaceuticals
Date/Time: Friday, October 6, 2017/12:30 PM-2:00 PM
Room: Poster Hall CD

1521. APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
Poster Abstract Session: Preclinical Study with New Antibiotics and Antifungals
Presenter: Ashraf Ibrahim, Ph.D., Harbor-UCLA Medical Center
Date/Time: Friday, October 6, 2017/12:30 PM-2:00 PM
Room: Poster Hall CD

1522. Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
Poster Abstract Session: Preclinical Study with New Antibiotics and Antifungals
Presenter: Marc Sharp, Ph.D., Linnaeus Bioscience
Date/Time: Friday, October 6, 2017/12:30 PM-2:00 PM
Room: Poster Hall CD

1529. Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis
Poster Abstract Session: Preclinical Study with New Antibiotics and Antifungals
Presenter: Wiley A. Schell, Duke University Medical Center
Date/Time: Friday, October 6, 2017/12:30 PM-2:00 PM
Room: Poster Hall CD

1840. First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Poster Abstract Session: Clinical Study with New Antibiotics and Antifungals
Presenter: Pamela Wedel, Amplyx Pharmaceuticals
Date/Time: Saturday, October 7, 2017/12:30 PM-2:00 PM
Room: Poster Hall CD

1860. Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability
Poster Abstract Session: Clinical Study with New Antibiotics and Antifungals
Presenter: Pamela Wedel, Amplyx Pharmaceuticals
Date/Time: Saturday, October 7, 2017/12:30 PM-2:00 PM
Room: Poster Hall CD

About APX001
APX001 is the prodrug of APX001A, which is a first-in-class small molecule drug candidate that inhibits the conserved fungal enzyme Gwt1, compromising growth of major fungal pathogens, including Candida and Aspergillus. APX001A has been evaluated extensively in preclinical studies, demonstrating broad-spectrum activity against common species of Candida spp., and Aspergillus spp., including multi drug resistant strains and rare, hard-to-treat molds including Fusarium spp., Scedosporium spp., and fungi from the Mucorales order.

About Amplyx Pharmaceuticals
Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. Amplyx has raised $118.5 million in venture capital and secured more than $10 million in grants from the National Institutes of Health to support its drug discovery and development efforts. For more information, please visit www.amplyx.com.

# # #

 

Contact:
Heidi Chokeir, Ph.D.
Managing Director
Canale Communications
(619) 849-5377
heidi@canalecomm.com